Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial by Shengyao Li et al.
STUDY PROTOCOL Open Access
Qing-Xin-Jie-Yu Granules in addition to
conventional treatment for patients with
stable coronary artery disease (QUEST Trial):
study protocol for a randomized controlled
trial
Shengyao Li1,2, Ming Guo1,2, Huimin Mao1,3, Zhuye Gao1, Hao Xu1* and Dazhuo Shi1*
Abstract
Background: Recurrent cardiovascular event remains high in stable coronary artery disease (SCAD), especially in
patients with multiple risk factors, despite a high rate of use conventional treatment. Traditional Chinese Medicine
(TCM) is a promising complementary and alternative medicine for treating SCAD, while evidence for its effect on
long-term survival is limited. This study was designed to test if Chinese herbal medicine in addition to conventional
treatment is more effective than conventional treatment alone in reducing major adverse cardiac event (MACE) for
SCAD patients with multiple risk factors during a 1-year follow-up.
Methods: This is a multicenter, placebo-controlled, double-blinded, randomized controlled clinical trial. A total
of 1500 patients are randomized in a 1:1 ratio to receive the Qing-Xin-Jie-Yu Granules (QXJYG) or the placebo
granules, twice daily for 6 months. The primary outcome is the combined outcomes including cardiac death,
nonfatal myocardial infarction and revascularization. The secondary outcome is the combined outcomes including
all-cause mortality, re-admission for acute coronary syndrome (ACS), heart failure, malignant supraventricular and
ventricular arrhythmia influencing hemodynamics, ischemic stroke, and other thromboembolic events during 1-year
follow-up. The assessment is performed at baseline (before randomization), 1, 3, 6, 9, and 12 months after
randomization.
Discussion: This is the first multicenter trial sponsored by the national funding of China to evaluate TCM in
combination with conventional treatment on 1-year survival in high-risk SCAD patients. If successful, it will provide
an evidence-based complementary therapeutic approach for reducing MACE from SCAD.
Trial registration: The trial was registered in the Chinese Clinical Trial Registry on December 28, 2013. The
registration number is ChiCTR-TRC-13004370.
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Background
Over the past three decades, preventive and therapeutic
agents have substantially improved the prognosis of
stable coronary artery disease (SCAD), however, cardio-
vascular event remains high, especially in high-risk
patients with additional multiple risk factors, such as
hypertension, hyperlipidemia and diabetes mellitus,
despite a high rate of use conventional treatment includ-
ing aspirin, statins, β-blockers and renin-angiotensin-
aldosterone system blockers, etc. [1]. In addition, in-
creasing evidence supports a vital role of inflammation
in the clinical instability of SCAD [2]. C-reactive protein
(CRP), a systemic inflammatory marker, adds prognostic
information to the cluster of traditional risk factors [3].
However, the novel anti-inflammatory drugs did not show
a positive effect on further reducing major adverse cardiac
event (MACE) [4, 5]. Therefore, it is necessary to seek
more effective strategies for inhibiting inflammation and
thus reducing the occurrence of MACE from SCAD.
Traditional Chinese Medicine (TCM) has been used
to treat CAD for thousands of years. A meta-analysis
of 70 randomized clinical trials including 9706 cases
of CAD demonstrated a beneficial effect of TCM on
clinical symptoms (odds ratio, 3.06 [95 % CI, 2.58 to
3.62]; P < 0.00001) and electrocardiograph (odds ratio,
2.46 [95 % CI, 2.16 to 2.80]; P < 0.00001) compared
with isosorbide dinitrate, and no serious adverse ef-
fects were reported [6]. However, another systematic
review pointed out that the majority of randomized
controlled trials on CAD with TCM are of “poor
quality”, thus more powerful evidence from high-
quality clinical trials are needed for future clinical
practice [7].
Qing-Xin-Jie-Yu Granules (QXJYG) have been used
to treat CAD for nearly two decades in mainland
China, and previous small-sample studies have dem-
onstrated that QXJYG relieved angina pectoris and de-
creased cholesterol of patients with CAD [8]. QXJYG
consist of five herbal granules, including Astragalus
membranaceus (Huangqi), Salvia miltiorrhiza Bunge
(Danshen), Ligusticum chuanxiong Hort (Chuanxiong),
Agastache rugosus (Huoxiang), and Coptis chinensis
(Huanglian). The pharmacological studies suggested
that the bioactive component or structural modifica-
tion of extracts from Huangqi [9], Danshen [10], and
Chuanxiong [11] had effects on cardiac protection,
plaque stabilization, inhibition of platelet aggregation,
etc., and these three Chinese herbs are also widely
used in TCM for treating CAD [12–14]. Moreover, ex-
tracts from Danshen and Huanglian exert anti-
inflammatory effects [15, 16], and clinical studies
showed that they decreased the level of high-sensitivity
CRP (hs-CRP) in patients with cardiovascular disease
[17, 18].
Therefore, QXJYG is worth investigating in high-risk
SCAD patients due to the pleiotropic effect. The
assumption is made that QXJYG in addition to conven-
tional treatment may be superior to reduce inflammation
of atherosclerosis and finally lead to the reduction of
MACE in high-risk SCAD patients. If successful, it will
provide an evidence-based complementary therapeutic




This study is designed as a multicenter, double-blind, ran-
domized, placebo-controlled, parallel-group, superiority
trial to test the hypothesis that QXJYG in addition to con-
ventional treatment is more effective than conventional
treatment alone in reducing MACE, which is defined as
cardiac death, nonfatal myocardial infarction and revascu-
larization, for SCAD patients with two or more athero-
genic risk factors during 1-year follow-up (see Fig. 1).
Design overview
The rigorous design, organization, and conduct of the trial
are supervised by a Steering Committee, which comprises
two members from each participating center in addition to
the chairman, scientific coordinator and statistician. Eight-
een clinical centers in mainland China will participate in
the trial, including Xiyuan Hospital of China Academy of
Chinese Medical Sciences, China-Japan Friendship Hos-
pital, The First Hospital of Tianjin University of Traditional
Chinese Medicine, etc. Data management and statistical
analyses will be performed solely by data handlers and data
analysts at Beijing Jiaotong University. This study follows
the international recommendations for interventional trials
[19]. (See the SPIRIT checklist in Additional file 1). All pa-
tients must personally sign and date an informed consent
document before randomization.
Inclusion criteria
The trial will recruit patients of both genders aged 18–75
years with evidence of CAD documented by previous
myocardial infarction (>3 months before screening), per-
cutaneous coronary revascularization (>1 month before
screening), angiographic or cardiac computed tomography
angiographic evidence of ≥50 % stenosis of ≥1 major cor-
onary artery. Also required are two or more of the follow-
ing four risks: a serum hs-CRP level ≥3 mg/L, a history of
hypertension, hyperlipidemia, and diabetes mellitus.
Exclusion criteria
The exclusion criteria are as follows:
(1)Combined with congenital or rheumatic heart
disease or severe heart failure;
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(2)Uncontrolled severe arrhythmia (including
paroxysmal ventricular tachycardia and
supraventricular arrhythmia), which can cause
hemodynamic responses;
(3)Acute cerebrovascular disease;
(4)Uncontrolled blood pressure, with a systolic blood
pressure ≥160 mmHg or a diastolic blood pressure
≥100 mmHg;
(5)Severe primary hepatic, renal, hematologic or
mental disorders;
(6)Major head, chest or abdominal surgery within
4 weeks or bleeding tendency;
(7)Pregnant or lactating women;
(8)Suspected to be allergic to Chinese herbal medicine;
(9)Currently participating in another clinical trial.
Recruitment
Inpatients and outpatients with SCAD in each center
will be screened. Each potentially eligible patient will be
assessed by an attending physician for whether the pa-
tient should be recruited. The aim, procedures, and pos-
sible side effects of the study granules will be explained
in detail to the patients; all patients will be asked to sign
a written informed consent form before randomization.
Neither financial nor nonfinancial incentives will be pro-
vided to attending physicians and patients for enrolment.
Randomization and treatment assignment
Patients are randomized in a 1:1 ratio through a
centrally controlled, computer-generated, site-stratified,
block randomization schedule. The study granules are
labeled with serial numbers, and each patient will be
assigned the lowest number available at each participat-
ing center. All patients, care providers, attending physi-
cians, laboratory staff and biostatisticians are blind to
treatment assignment until the database has been
locked. Randomization started on October, 2014. Enrol-
ment of 1500 patients is expected to be completed in
August 2016.
Interventions
Eligible patients will be allocated to receive QXJYG or
placebo for 6 successive months, in addition to conven-
tional treatment including antiplatelet, lipid-lowing, anti-
hypertensive or antidiabetic therapy, etc., according to
the guidelines [20]. The QXJYG and placebo granules
were produced and packed in a single batch (Production
batch number:1405001H) by China Resources Sanjiu
Fig. 1 Study flow of the QUEST Trial
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Medical and Pharmaceutical Co., Ltd., Shenzhen, China.,
which has no conflict of interest relevant to this study.
The test results of drug quality were consistent with the
Chinese Medicine Standards of the State Food and Drug
Administration (SFDA). The placebo granules are com-
posed of 10 % crude drug of QXJYG and 90 % starch,
which have the identical appearance, smell, and scent as
the active treatment granules. Patients will be instructed
to dissolve the granules in 150 mL hot water and take
orally twice daily for 6 successive months. Any other
Chinese herbal decoction or Chinese patent medicine
for treating CAD is prohibited during the study.
Outcomes
The combined primary outcomes include cardiac death,
nonfatal myocardial infarction, and revascularization.
The combined secondary outcomes include all-cause
mortality, re-admission for acute coronary syndrome
(ACS), heart failure, malignant supraventricular and ven-
tricular arrhythmia influencing hemodynamics, ischemic
stroke, and other thromboembolic events during 1-year
follow-up.
Hs-CRP, blood lipids, platelet aggregation rate, echo-
cardiography, electrocardiogram, and Seattle Angina
Questionnaire (SAQ) will also be monitored periodically.
Safety assessment
Safety will be monitored up to 6 months after interven-
tion and evaluated based on the incidence of adverse
events (AEs) including clinically significant changes in
physical examinations, vital signs, and standard clinical
laboratory tests (complete blood count, blood biochem-
ical examination, coagulation [including prothrombin
time (PT), thrombin time (TT), international normalized
ratio (INR), activated partial thromboplastin time (APTT),
and fibrinogen] and urinalysis). The National Cancer In-
stitute’s Common Terminology Criteria for Adverse
Events (CTCAE) v4.0 grading system was used to classify
the nature and severity of the AEs [21].
Follow-up
The follow-up for all patients will be scheduled at 1, 3,
6, 9, and 12 months (see Additional file 2). The primary
and secondary outcomes as well as safety will be evalu-
ated at each follow-up. If severe adverse events (SAEs)
occur, the attending physician must report to the princi-
pal investigator and ethics committee immediately, who
will decide whether or not to continue the treatment.
Patients are also free to continue or discontinue the
study at any time during the trial. Additionally, any
medication change and events leading to therapy inter-
ruption will be recorded on the case record form (CRF).
Compliance
A mobile application will be used to remind the patients
automatically at each follow-up appointment. In addition,
each patient will be asked to offer at least two telephone
numbers in order to be contacted in time. Furthermore,
attending physicians will be responsible for each patient’s
questions.
To assess medication adherence, patients will be asked
to return the unused granules. Unused granules account-
ing for more than 20 % of the total granules will be de-
fined as nonadherence. The reasons for nonadherence
(e.g., discontinuation of intervention owing to harm or
unsatisfactory efficacy) will be recorded on the CRF.
Sample size
The sample size was calculated based on the expected
reduction of incidence in MACE from pre- to post-
treatment at 1 year. A previous study suggested that the
MACE (death, myocardial infarction, and urgent revas-
cularization) incidence in high-risk patients with SCAD
is about 10 % within 1 year [1]. Assuming a MACE inci-
dence reduction to 7 % following treatment with QXJYG
added, and given a type I error rate of alpha = 0.05, a
power of 80 % (type II error rate of beta = 0.2), the
sample size for one arm needed to be 630, resulting
in n = 2 × 630 = 1260 patients. Considering a dropout rate
of 20 %, a total of 1512 patients needed to be allocated to
reach the required number of patients for the efficacy
analysis. For convenience of randomization, we decided to
recruit 1500 patients.
Statistical approach
Continuous variables will be presented as the mean ±
standard deviation (SD), median or interquartile range
(IQR), and as frequencies or percentages for categorical
variables. The comparability of the characteristics be-
tween the two groups will be assessed using a two-
sample Student’s t test for continuous variables and the
chi-square test or Wilcoxon test, when appropriate, for
categorical variables. For the SAQ scores, the analysis of
covariance (ANCOVA) will be used to compare the
change from baseline to 1 year between the QXJYG
group and the placebo group [22]. Questionnaire score
data, known as nonnormally distributed, will be trans-
formed or analyzed with nonparametric ANCOVA. If
appropriate, multivariable linear models will be used to
assess the association between independent predictors
and the continuous endpoints of the trial. Cumulative
event rates of an outcome in the QXJYG and the pla-
cebo groups, respectively, will be estimated using the
Kaplan-Meier method, and differences between the
curves will be tested using the log-rank method. The
crude and adjusted hazard ratio and their 95 % confidence
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intervals will be estimated by the Cox proportional haz-
ards regression model.
The primary outcome will be conducted on the
intention-to-treat (ITT) analysis. The ITT set includes
all patients randomized to treatment. The per protocol
set consists of all patients with no major deviation from
the protocol and with an overall treatment adherence
rate of 80 % or higher at the end of the study. The safety
set consists of ITT patients excluding those who do not
take any study medication or who have no record of
follow-up after randomization. We will assess the effect
that any missing data might have on the results by sensi-
tivity analysis of augmented data sets. Dropouts will be
included in the analysis by modern imputation methods
for missing data.
We plan to conduct three subgroup analyses: first, we
will compare hazard ratios of MACE based upon the
level of hs-CRP (below 3 mg/L vs. greater than or equal
to 3 mg/L). Second, we will compare the hazard ratios of
MACE between SCAD patients with diabetes or not.
Finally, we will compare the hazard ratios of MACE
between men and women with SCAD.
For all analyses, a value of P < 0.05 is considered statisti-
cally significant, and all tests are two-tailed. P values will
be reported to four decimal places. All analyses will be
conducted using R software version 2.15.1 (http://www.R-
project.org/), unless otherwise noted.
Data management and monitoring
Data from all participating centers will be imported in
the clinical data management system (CDMS) with the
website at http://www.xyedc.com. Data and materials
supporting the conclusions of this trial will be available
in this system. A password system will be utilized to
control access. Data integrity will be achieved through
several mechanisms including referential data rules, valid
values, range checks and consistency checks against data
already stored in the database. Missing data or specific
errors in the data will be detected by programs. Written
documentation of changes will be available via electronic
logs and audit trails. Original CRF will be kept at the
participating center for 5 years after completion of the
study.
Safety monitoring
A Data and Safety Monitoring Board (DSMB) will be in
charge of safety reviews, and will include at least two in-
dependent faculty members from the participating cen-
ter. The safety will be evaluated for the first time when
approximately 20 % patients have 6 months of data
available. Subsequently, the DSMB will perform the in-
terim analysis for safety with the support of the statis-
tical group when approximately 50 % patients have
6 months of data available. In addition, the DSMB will
conduct at least one on-site monitoring visit during the
study to ensure that each participating center complies
with the study protocol and Good Clinical Practice
(GCP) principles; the data and SAEs are accurately and
appropriately recorded on the CRF. When SAEs occur,
the DSMB will perform unblinding immediately.
Discussion
According to our knowledge, this is the first multicenter
trial sponsored by the national funding of China to
evaluate TCM in combination with conventional treat-
ment on 1-year survival in high-risk SCAD patients.
Atherogenic risk factors including hypertension,
hyperlipidemia, and diabetes are common in CAD pa-
tients, and clustering of them has a higher age-adjusted,
long-term mortality risk [23]. In addition, accumulating
evidence has revealed that all these traditional athero-
genic risk factors are closely associated with an increased
level of CRP, an inflammatory marker with additional
prognostic value [24]. A study showed that in SCAD
patients, the CRP concentration in the fifth quintile
(>3.6 mg/L) showed an about twofold increase in MACE,
compared with the first four quintiles [25]. This is in
accordance with the consensus view that inflammation
has a role in the pathogenesis of cardiovascular events.
Therefore, inhibiting chronic inflammation has been
regarded a potential strategy to reduce MACE from
SCAD.
Chinese herbs have shown multifactorial cardiovascu-
lar protective effects, such as lowing plasma lipids [9],
reducing oxidative stress [10], and inhibiting platelet ag-
gregation [11], etc. In addition, the anti-inflammatory ef-
fects of Chinese herbs have gained much attention
recently. Danshen and Huanglian, the two herbs used in
QXJYG, also have been demonstrated in many animal or
cell culture models to inhibit inflammatory respondence.
In ApoE-deficient mice fed with a high cholesterol diet,
salvianolic acid B, an extract from Danshen, reduced
metalloproteinases-2 (MMP-2) and MMP-9 expression
significantly [26]. In human umbilical vein endothelial
cells as well as platelets, treatment with extract from
Danshen attenuated tumor necrosis factor alpha (TNF-
α)-induced expression of CD40. Furthermore, the ex-
pression of vascular cell adhesion molecule-1 (VCAM-1)
and intercellular adhesion molecule-1 (ICAM-1) as well
as the release of soluble VCAM-1, ICAM-1, interleukin-
6 (IL-6), IL-8 and monocyte chemoattractant protein 1
(MCP-1) were downregulated [27]. Berberine, an extract
from Huanglian, also decreased serum levels of TNF-α
and IL-6 in rats with isoproterenol-induced acute myo-
cardial ischemia [28]. This gives a stimulus for large
controlled trials to examine the long-term effects of
QXJYG in CAD patients, especially those in a high
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inflammatory state (a serum hs-CRP level ≥3 mg/L, with
additional multiple atherogenic risk factors).
Granules have been widely used in mainland China.
Our study QXJYG granules were produced strictly in
compliance with standards of Good Manufactory Prac-
tice (GMP) and Chinese Pharmacopoeia 2010. The
chemical compositions of the final products were ana-
lyzed for contamination with heavy metals, toxic ele-
ments, microbe and pesticide residues; the final
products were analyzed for stability and adherence to
quality standards of the CFDA. The fingerprint of
QXJYG will be conducted to ensure the stability and
homogeneity of the composition. The placebo granules
have the identical appearance, smell, and scent as the
active treatment granules. Granules were distributed
to the 18 study sites with the same batch number.
The company that provided the granules does not
participate in the design, analysis, or interpretation of
the study.
It should be noted that our study has limitations. First,
the study is conducted only in mainland China, and
whether the results from this trial can be applied to
other ethnic groups is uncertain. However, the partici-
pating centers are located in different geographic areas
in mainland China, and national minorities are also in-
volved. Therefore, the recruited patients guarantee a
certain representativeness. Second, the duration of
follow-up is designed relatively short. The continuation
of follow-up after the end of the study has been planned
in order to assess the long-term outcome.
In conclusion, this trial is designed to demonstrate
that the addition of QXJYG to conventional treatment
will reduce the inflammation of atherosclerosis and fi-
nally lead to the reduction of MACE in high-risk SCAD
patients.
Trial status
The trial has currently recruited 1202 patients since
October 2014, of which 906 have completed the 6-month
follow-up. Thirty patients experienced MACE, but their
allocated group is still bind. No SAEs have occurred to
date.
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